This is hereby announced
Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. has successfully completed the relevant work of its shareholding system reform and was officially renamed Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. on March 27, 2026. This renaming marks a solid step forward for the company on the path of market-oriented reform and standardized governance, ushering in a new journey of high-quality development.
About Us
Baiyunshan Hanfang is a high-tech enterprise wholly owned by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (GPH), an A+H share-listed company under GPH. The company focuses on the biopharmaceutical and health industries, specializing in the R&D, production, and sales of specialty APIs, lipid emulsion excipients, health foods, and special medical foods.
As a “Science and Technology Reform Enterprise” recognized by the State-owned Assets Supervision and Administration Commission of the State Council and a “Little Giant” enterprise specializing in niche fields certified by the Ministry of Industry and Information Technology, the company relies on the “National Engineering Research Center for Traditional Chinese Medicine Manufacturing Process Technology and New Drug Creation.” It maintains a leading position in the specialty API sub-sector, has built China’s largest pharmaceutical lipid excipient production base with internationally advanced technology, and continues to drive high-quality development in the pharmaceutical and health industries.
A Steady Path of Reform
As an active practitioner of state-owned enterprise reform, Baiyunshan Hanfang has consistently aligned itself with the requirements of the action plan for deepening and upgrading SOE reform, steadily advancing all reform initiatives:
In November 2025, the company successfully completed its mixed-ownership reform, bringing in five strategic investors and implementing equity incentives for key technical personnel and managerial staff, thereby establishing a diversified equity structure and achieving a crucial breakthrough in the market-oriented reform of state-owned enterprises. Since then, with the core objectives of clarifying property rights and establishing a modern corporate system, the company has continued to deepen its shareholding reform, constantly improving a governance framework characterized by clear responsibilities and efficient operations, laying a solid foundation for long-term development.
A New Beginning, A New Promise
The new name carries a new mission, and this fresh start opens up a new journey. Following the renaming, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will remain true to its original aspirations and bravely shoulder its mission, guided by the vision of “becoming a trusted guardian of health for families worldwide” and committed to the mission of “focusing on innovation, creating outstanding products, and contributing to human health and longevity at a high quality level.”
Looking ahead, the company will continue to deepen its expertise in the pharmaceutical and health sectors, striving to create a new landscape of high-quality development, making greater contributions to GPH’s endeavor to build a world-class, science-and-innovation-driven pharmaceutical and health industry group, injecting fresh momentum into the implementation of the “Healthy China” strategy and the thriving development of the pharmaceutical and health industries, and writing a new chapter!
We sincerely thank leaders at all levels, partners, and friends from all sectors of society for their longstanding care and support, and look forward to continuing to join hands with you to build a healthy future together!
